Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 3, 28 April 2023

Open Access | Article

Development of Current COVID-19 Vaccines, A Review

Shaofeng Xu * 1
1 Biochemical engineering department, UCL

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 3, 71-79
Published 28 April 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Shaofeng Xu. Development of Current COVID-19 Vaccines, A Review. TNS (2023) Vol. 3: 71-79. DOI: 10.54254/2753-8818/3/20220183.

Abstract

The virus known as severe acute respiratory coronavirus 2 is extremely pathogenic. and has already give rise to worldwide contagious pandemic. SARS-CoV-2 new variations, particularly the Omicron strain, are a major global concern. To reduce the spread of virus, considerable efforts have been made towards the development of effective vaccines and drugs against SRAS-CoV-2. The current available vaccines include inactivated vaccines (Sinopharm and Sinovac), protein-based vaccines (Novavax), DNA vaccines, RNA vaccines (Moderna and Pfizer), viral vector vaccines (Oxford-AstraZeneca). These various vaccinations act in different ways to improve human immunity with their own strengths and drawbacks but both of them could work very effectively to prevent infection. In this review, recently significant progress in the development of COVID-19 vaccination, including vaccine type, efficacy and safety issues, and variant protection are summarized.

Keywords

BNT162b2 (Pfizer), ChAdOx1 nCov-19 (AstraZeneca) and mRNA-1273 (Moderna), Sars-Cov-2

References

1. Padron-Regalado, E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect. Dis. Ther. 9, 255–274 (2020).

2. Ortiz-Prado, E. et al. Clinical, molecular and epidemiological characterization of the SARS- CoV2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn. Microbiol. Infect. Dis. 98, 115094 (2020).

3. Du, L. et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226(2009)

4. https://www.bbc.co.uk/news/health-55302595

5. https://www.medicalnewstoday.com/articles/live-updates-coronavirus-COVID-19#1

6. https://www.who.int/emergencies/diseases/novel-coronavirus- 2019?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQo

7. https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-COVID-19- vaccine-what-you-need-to-know

8. BC center for disease control. World Health Organization (WHO) Emergency Use Authorization qualified COVID-19 vaccines. Availble from: http://www.bccdc.ca/HealthInfo-Site/Documents/COVID-19_vaccine/WHO-EUA-qualified-COVID-vaccines.pdf

9. C. Fett, M.L. DeDiego, J.A. Regla-Nava, L. Enjuanes, S. Perlman

10. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein J Virol, 877 (2013), pp. 6551-6559

11. Duduzile Ndwandwe, Charles S Wiysonge,COVID-19 vaccines,Current Opinion in Immunology,Volume 71,2021,Pages 111-116,ISSN 0952-7915, https://doi.org/10.1016/j.coi.2021.07.003.

12. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35–45. doi:10.1001/jama.2021.8565

13. C.L. Hsieh, J.A. Goldsmith, J.M. Schaub, A.M. DiVenere, H.C. Kuo, K. Javanmardi, K.C. Le, D. Wrapp, A.G. Lee, Y. Liu, et al. Structure-based design of prefusion-stabilized SARS- CoV-2 spikes Science, 369 (2020), pp. 1501-1505

14. D. Lemaire, T. Barbosa, P. Rihet. Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology. Braz J Med Biol Res, 45 (2012), pp. 376-385

15. Dunkle Lisa M., Kotloff Karen L., Gay Cynthia L., Áñez Germán, Adelglass Jeffrey M., Barrat Hernández Alejandro Q., Harper Wayne L., Duncanson Daniel M., McArthur Monica A., Florescu Diana F., McClelland R. Scott, Garcia-Fragoso Veronica, Riesenberg Robert A., Musante David B., Fried David L., Safirstein Beth E., McKenzie Mark, Jeanfreau Robert J., Kingsley Jeffrey K., Henderson Jeffrey A., Lane Dakotah C., Ruíz-Palacios Guillermo M., Corey Lawrence, Neuzil Kathleen M., Coombs Robert W., Greninger Alex L., Hutter Julia, Ake Julie A., Smith Katherine, Woo Wayne, Cho Iksung, Glenn Gregory M., Dubovsky Filip. (2022) Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med 386:6, 531-543.

16. Y. Chen, L. Li. SARS-CoV-2: virus dynamics and host response. Lancet Infect Dis, 20 (2020), pp. 515-516

17. DNA vaccines". World Health Organization. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575. doi:10.1001/jama.2021.2927.

18. Sandbrink, J. and Shattock, R., 2020. RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. Frontiers in Immunology, 11.

19. Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector. J Virol (2003) 77:10394–403. doi: 10.1128/jvi.77.19.10394-10403.2003

20. Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self Amplifying RNA Vaccines Give Equivalent Protection against Inflfluenza to mRNA Vaccines but at Much Lower Doses. Mol Ther (2018) 26:446–55. doi: 10.1016/j.ymthe.2017.11.017

21. Kaukinen U, Lyytikäinen S, Mikkola S, Lönnberg H. The reactivity of phosphodiester bonds within linear single-stranded oligoribonucleotides in strongly dependent on the base sequence. Nucleic Acids Res (2002) 30:468–74. doi: 10.1093/nar/30.2.468

22. Francis, A.I., Ghany, S., Gilkes, T. and Umakanthan, S. (2021). Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgraduate Medical Journal, [online] p.postgradmedj-2021-140654. Available at: https://pmj.bmj.com/content/postgradmedj/early/2021/08/05/postgradmedj-2021- 140654.full.pdf.

23. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID- 19 vaccine. N Engl J Med 2020;383:2603–15.doi:10.1056/NEJMoa2034577pmid:

24. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403 16.doi:10.1056/NEJMoa2035389pmid:

25. C. Keech, G. Albert, I. Cho, A.Robertson, P. Reed, S. Neal, J.S.Plested, M. Zhu, S. Cloney- Clark, H.Zhou, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 383 (2020), pp. 2320-2332

26. E. Callaway. The race for coronavirus vaccines: a graphical guide. Nature, 580 (2020), pp. 576- 577

27. WHO. COVID-19 Vaccine Tracker and Landscape (2021). From: https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines

28. García-Montero C, Fraile-Martínez O, Bravo C, et al. An updated review of SARS- CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines 2021;9. doi:10.3390/vaccines9050433.

29. Sumirtanurdin R, Barliana MI. Coronavirus disease 2019 vaccine development: an overview. Viral Immunol 2021;34:134–44.

30. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021;384:2187–201.

31. https://www.bbc.co.uk/news/health-55659820

32. https://www.bbc.co.uk/news/health-59758784

33. https://www.bbc.co.uk/news/health-59696499

34. Voysey, M. and Pollard, A.J. (2020). ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors’ reply. The Lancet, 396(10261), pp.1486–1487.

35. Alimehmeti, I. (2021). Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2. Albanian Journal of Trauma and Emergency Surgery, 5(1), pp.791– 796.

36. Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M.A., Hernán, M.A., Lipsitch, M., Reis, B. and Balicer, R.D. (2021). BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England Journal of Medicine, [online] 384. Available at: https://pubmed.ncbi.nlm.nih.gov/33626250/.

37. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187-189.

38. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. August 24, 2021

39. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med 2022;386:340-350.

40. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. August 30, 2021

41. Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. August 5, 2021

42. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 2021;385:1393-1400.

43. New England Journal of Medicine. 2022. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant | NEJM. [online] Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2119451> [Accessed 10 April 2022]

44. Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P. and Cao, J.-M. (2020). SARS- CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in Cellular and Infection Microbiology, 10.

45. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA COVID–19 Vaccine. N Engl J Med. 2020;383(27):2603–15.

46. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA– 1273 SARS-CoV–2 Vaccine. N Engl J Med. 2021;384(5):403–16.

47. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021;385:2348-2360.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
ISBN (Print)
978-1-915371-25-6
ISBN (Online)
978-1-915371-26-3
Published Date
28 April 2023
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/3/20220183
Copyright
28 April 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated